You have full text access to this OnlineOpen article

Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine

  1. A. W. Zuercher1,
  2. M. A. Imboden1,
  3. S. Jampen1,
  4. D. Bosse1,*,
  5. M. Ulrich1,
  6. H. Chtioui2,
  7. B. H. Lauterburg2,
  8. A. B. Lang1

Article first published online: 18 NOV 2005

DOI: 10.1111/j.1365-2249.2005.02964.x

Issue

Clinical & Experimental Immunology

Clinical & Experimental Immunology

Volume 143, Issue 1, pages 132–138, January 2006

Additional Information

How to Cite

Zuercher, A. W., Imboden, M. A., Jampen, S., Bosse, D., Ulrich, M., Chtioui, H., Lauterburg, B. H. and Lang, A. B. (2006), Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clinical & Experimental Immunology, 143: 132–138. doi: 10.1111/j.1365-2249.2005.02964.x

Author Information

  1. 1

    Berna Biotech Ltd, Berne, Switzerland, and

  2. 2

    Clinical Investigation Unit, Inselspital, Berne, Switzerland

*Dietrich Bosse, Berna Biotech Ltd, Rehhagstrasse 79, CH-3018 Bern, Switzerland. E-mail: dietrich.bosse@bernabiotech.com

Publication History

  1. Issue published online: 18 NOV 2005
  2. Article first published online: 18 NOV 2005
  3. Accepted for publication 20 September 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (132K)

References

  • 1
    Koch C, Høiby N. Pathogenesis of cystic fibrosis. Lancet 1993; 341: 1065–9.
  • 2
    Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002; 15: 194–222.
  • 3
    Cryz SJ Jr, Fuerer E, Cross AS et al. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest 1987; 80: 51–6.
  • 4
    Cryz SJ Jr, Sadoff JC, Ohman D et al. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. J Lab Clin Med 1988; 111: 701–7.
  • 5
    Cryz SJ Jr, Wedgewood J, Lang AB et al. Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa. J Infect Dis 1994; 169: 1159–62.
  • 6
    Cryz SJ Jr, Lang A, Rudeberg A et al. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Behring Inst Mitt 1997; 98: 345–9.
  • 7
    Schaad UB, Lang AB, Wedgwood J et al. Safety and immunogenicity of Pseudomonas aeruginosa polyvalent conjugate A vaccine in cystic fibrosis. Lancet 1991; 338: 1236–7.
  • 8
    Lang AB, Schaad UB, Ruedeberg A et al. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr 1995; 127: 711–7.
  • 9
    Lang AB, Rüdeberg A, Schöni MH et al. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 2004; 23: 504–10.
  • 10
    Johansen HK, Hougen HP, Cryz SJ Jr et al. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Am J Respir Crit Care Med 1995; 152: 1337–46.
  • 11
    Moser C, Johansen HK, Song Z et al. Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. APMIS 1997; 105: 838–42.
    Direct Link:
  • 12
    Moser C, Hougen HP, Song Z et al. Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T-helper cell response. APMIS 1999; 107: 1093–100.
    Direct Link:
  • 13
    Moser C, Kjaergaard S, Pressler T et al. The immune response to chronic Pseudomonas aeruginosa lung infection in cycstic fibrosis patients is predominantly of the Th2 type. APMIS 2000; 108: 329–35.
    Direct Link:
  • 14
    Kumoboj KK, Kirchner HL, Kimmel R et al. Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier. J Infect Dis 2003; 187: 1629–38.
  • 15
    Kumboj KK, King CL, Greenspan NS et al. Immunization with Haemophilus influenzaType b-CRM197 conjugate vaccine elicits a mixed Th1 and Th2 CD4+T cell cytokine response that correlates with the isotype of antipolysaccharide antibody. J Infect Dis 2001; 184: 931–5.
  • 16
    Wuorimaa T, Kayhty H, Eskola J et al. Activation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine. Scand J Immunol 2001; 53: 422–8.
    Direct Link:
  • 17
    Hoshino Y, Morishima T, Kimura H et al. Antigen-driven expansion and contraction of CD8+-activated T cells in primary EBV infection. J Immunol 1999; 163: 5735–40.
  • 18
    McElhaney JE, Pinkoski M, Meneilly GS. Changes in CD45 isoform expression vary according to the duration of T-cell memory vaccination. Clin Lab Diagn 1995; 2: 73–81.
  • 19
    Zepp F, Knuf M, Habermehl P et al. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun 1996; 64: 4078–84.
  • 20
    Eberl G, Brawand P, MacDonald HR. Selective bystander proliferation of memory CD4+ and CD8+T cells upon NK T cell or T cell activation. J Immunol 2000; 165: 4305–11.
View Full Article (HTML) Get PDF (132K)